Cargando…

829. 5-Flucytosine Longitudinal Antifungal Susceptibility Testing of Cryptococcus neoformans: A Sub-study of the EnACT Trial Testing Oral Amphotericin

BACKGROUND: The EnACT trial was a phase 2 randomized clinical trial conducted in Uganda, which evaluated a novel orally delivered lipid nanocrystal (LNC) amphotericin B for treatment of cryptococcal meningitis. Oral LNC amphotericin B applies nanotechnology, which hopes to improve intracellular drug...

Descripción completa

Detalles Bibliográficos
Autores principales:	McHale, Thomas, Akampurira, Andrew, Gerlach, Elliot, Atukunda, Mucunguzi, Nicol, Melanie R, Williams, Darlisha A, Meya, David, Boulware, David R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678681/ http://dx.doi.org/10.1093/ofid/ofad500.874

Ejemplares similares

Phase I EnACT Trial of the Safety and Tolerability of a Novel Oral Formulation of Amphotericin B
por: Skipper, Caleb P., et al.
Publicado: (2020)

Adaptation to Fluconazole via Aneuploidy Enables Cross-Adaptation to Amphotericin B and Flucytosine in Cryptococcus neoformans
por: Yang, Feng, et al.
Publicado: (2021)

Carbon Dioxide Potentiates Flucytosine Susceptibility in Cryptococcus neoformans
por: Jezewski, Andrew J., et al.
Publicado: (2023)

ATI-2307 Exhibits Equivalent Antifungal Activity in Cryptococcus neoformans Clinical Isolates With High and Low Fluconazole IC(50)
por: Gerlach, Elliot S., et al.
Publicado: (2021)

869. Oral Encochleated Amphotericin B for Cryptococcal Meningitis: a Phase II Randomized Trial
por: Atukunda, Mucunguzi, et al.
Publicado: (2022)

Identification of Pathogen Genomic Differences That Impact Human Immune Response and Disease during Cryptococcus neoformans Infection
por: Gerstein, Aleeza C., et al.
Publicado: (2019)

Acridine orange fluorescent microscopy is more sensitive than India ink light microscopy in the rapid detection of cryptococcosis among CrAg positive HIV patients
por: Kwizera, Richard, et al.
Publicado: (2017)

P092 Otilonium bromide is a potent antifungal agent against fluconazole- and flucytosine-resistant Cryptococcus neoformans strains
por: Zhen, Cheng, et al.
Publicado: (2022)

Effects of environmental factors on sensitivity of Cryptococcus neoformans to fluconazole and amphotericin B
por: Carlson, Tyler, et al.
Publicado: (2021)

Major Role for Amphotericin B–Flucytosine Combination in Severe Cryptococcosis
por: Dromer, Françoise, et al.
Publicado: (2008)

Cryptococcus neoformans Ex Vivo Capsule Size Is Associated With Intracranial Pressure and Host Immune Response in HIV-associated Cryptococcal Meningitis
por: Robertson, Emma J., et al.
Publicado: (2014)

Antiphagocytic protein 1 increases the susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole
por: Ghaffar, Muhammad, et al.
Publicado: (2019)

Flucytosine and Amphotericin B Coadministration Induces Dose-Related Renal Injury
por: Folk, Alexandra, et al.
Publicado: (2017)

Synergistic antifungal interaction of N-(butylcarbamothioyl) benzamide and amphotericin B against Cryptococcus neoformans
por: Andriani, Gabriella Maria, et al.
Publicado: (2023)

Evaluation of Hepatotoxicity with Treatment Doses of Flucytosine and Amphotericin B for Invasive Fungal Infections
por: Folk, Alexandra, et al.
Publicado: (2016)

Factors Influencing the Nitrogen-Source Dependent Flucytosine Resistance in Cryptococcus Species
por: Yang, Dong-Hoon, et al.
Publicado: (2023)

De Novo Pyrimidine Biosynthesis Connects Cell Integrity to Amphotericin B Susceptibility in Cryptococcus neoformans
por: Banerjee, Dithi, et al.
Publicado: (2016)

Combined effect of furanone fluconazole and amphotericin B against biofilms formed from Cryptococcus neoformans
por: Meenakumari, Kirishnamoorthy, et al.
Publicado: (2021)

The Cryptococcus neoformans Transcriptome at the Site of Human Meningitis
por: Chen, Yuan, et al.
Publicado: (2014)

Lack of Association between Fluconazole Susceptibility and ERG11 Nucleotide Polymorphisms in Cryptococcus neoformans Clinical Isolates from Uganda
por: Atim, Priscilla Belbir, et al.
Publicado: (2022)

etymologia: Cryptococcus neoformans
Publicado: (2008)

The capsule of Cryptococcus neoformans
por: Casadevall, Arturo, et al.
Publicado: (2018)

Limitation of the Benefit of Amphotericin-Flucytosine Combination Therapy in Patients With Lower Conscious Level: An Ecological Fallacy?
por: Wolbers, Marcel, et al.
Publicado: (2015)

An Elderly Patient with Pulmonary Cryptococcosis with Mediastinal Lymphadenopathy Who Was Successfully Treated with Amphotericin B and Flucytosine
por: Fujimoto, Shusaku, et al.
Publicado: (2020)

Comparison of amphotericin B deoxycholate in combination with either flucytosine or fluconazole, and voriconazole plus flucytosine for the treatment of HIV-associated cryptococcal meningitis: a prospective multicenter study in China
por: Zhao, Ting, et al.
Publicado: (2022)

Standardized Electrolyte Supplementation and Fluid Management Improves Survival During Amphotericin Therapy for Cryptococcal Meningitis in Resource-Limited Settings
por: Bahr, Nathan C., et al.
Publicado: (2014)

Triclosan Demonstrates Synergic Effect with Amphotericin B and Fluconazole and Induces Apoptosis-Like Cell Death in Cryptococcus neoformans
por: Movahed, Elaheh, et al.
Publicado: (2016)

The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of Cryptococcus neoformans
por: Hai, Trieu Phan, et al.
Publicado: (2019)

Antifungal efficacy of amphotericin B encapsulated fibrin microsphere for treating Cryptococcus neoformans infection in Swiss albino mice
por: Khan, Azmat Ali, et al.
Publicado: (2016)

Antifungal Susceptibilities of Cryptococcus neoformans
por: Archibald, Lennox K., et al.
Publicado: (2004)

Environmental Status of Cryptococcus neoformans and Cryptococcus gattii in Colombia
por: Serna-Espinosa, Briggith-Nathalia, et al.
Publicado: (2021)

Management of amphotericin-induced phlebitis among HIV patients with cryptococcal meningitis in a resource-limited setting: a prospective cohort study
por: Ahimbisibwe, Cynthia, et al.
Publicado: (2019)

Flucytosine and its clinical usage
por: Sigera, L. Shamithra M., et al.
Publicado: (2023)

Mechanisms of Flucytosine Resistance in Cryptococcus gattii May Be Independent of the FCY2-FCY1-FUR1 Pathway
por: Vu, Kiem, et al.
Publicado: (2017)

Correction for Banerjee et al., “De Novo Pyrimidine Biosynthesis Connects Cell Integrity to Amphotericin B Susceptibility in Cryptococcus neoformans”
por: Banerjee, Dithi, et al.
Publicado: (2023)

Cryptococcus Species Other Than Cryptococcus neoformans and Cryptococcus gattii: Are They Clinically Significant?
por: Cano, Edison J, et al.
Publicado: (2020)

Methods for Antifungal Susceptibility Testing of the Cryptococcus neoformans/C. gattii Complex: Strengths and Limitations
por: Espinel-Ingroff, Ana, et al.
Publicado: (2023)

829 Utility of universal COVID-19 testing in a midwest pregnant population
por: Forde, Braxton, et al.
Publicado: (2021)

Mathematical modeling of pathogenicity of Cryptococcus neoformans
por: Garcia, Jacqueline, et al.
Publicado: (2008)

Cryptococcus neoformans: Tripping on Acid in the Phagolysosome
por: DeLeon-Rodriguez, Carlos M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_lcg5jh8oguivtjqg9mh8539mhg